Thermo Fisher Scientific Inc.
TMO
$629.27
+0.27%
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing analytical instruments, laboratory equipment, diagnostics consumables, and life science reagents to pharmaceutical, biotech, academic, and clinical customers. The company operates through four segments—analytical technologies, specialty diagnostic products, life science solutions, and lab products and services (including CRO services)—making it a diversified, essential supplier across the research and applied markets. As the largest player in the life science tools industry, Thermo Fisher is recognized for its broad portfolio, scale, and recurring revenue streams. The current investor narrative centers on the company's ability to sustain mid-single-digit organic growth, expand margins through operational excellence, and leverage its high-growth bioproduction and clinical research businesses, while navigating modest inflationary pressures and geopolitical uncertainties.…
TMO
Thermo Fisher Scientific Inc.
$629.27
Investment Opinion: Should I buy TMO Today?
Based on the analysis, TMO is rated a Hold. The consensus is Buy with an average target of $631.42, but the current price of $629.27 leaves only 0.34% upside, indicating the stock is fairly valued. The thesis is that TMO is a high-quality company with strong fundamentals, but the risk-reward is balanced at current levels.
Sign up to view all
TMO 12-Month Price Forecast
The AI assessment is neutral, as the stock's strong fundamentals are offset by its premium valuation and limited upside. The company is executing well, but the market has already priced in much of the good news. To upgrade to bullish, we would need to see evidence of accelerating growth that justifies the valuation, such as revenue growth above 8% or margin expansion. To downgrade to bearish, we would need to see a deterioration in fundamentals, such as a decline in revenue growth or a significant margin miss. The current risk-reward is balanced, making a neutral stance appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $631.42 and implied upside of +0.3% versus the current price.
Average Target
$631.42
0 analysts
Implied Upside
+0.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
Thermo Fisher is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.54 (where 1 is Strong Buy and 5 is Sell). The average price target is $631.42, implying a modest 0.34% upside from the current price of $629.27, suggesting the stock is fairly valued near its target. The distribution of ratings is bullish, with no Sell ratings and a majority of Buy or Outperform ratings, reflecting strong confidence in the company's fundamentals and growth outlook.
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced but slightly bullish case. The company demonstrates solid revenue acceleration, strong profitability, and a diversified portfolio, supported by a bullish analyst consensus. However, the stock trades at a premium valuation with limited upside to the average target, and debt and inflation risks could temper gains. The key tension is whether the expected earnings growth (implied by the forward P/E gap) materializes to justify the premium. If growth sustains, the stock can re-rate higher; if not, multiple compression could lead to significant downside. Overall, the evidence slightly favors the bulls given the strong operational performance and market position, but the risk-reward is not compelling for new entries at current levels.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 6.18% YoY to $11.005B, up from 4.7% in Q1 2025, showing acceleration. The trailing twelve-month revenue trend is consistently upward, with Q4 2025 reaching $12.215B, indicating strong demand across segments.
- Strong Analyst Consensus: 26 analysts rate TMO a Buy with a mean score of 1.54 (1=Strong Buy, 5=Sell), and no Sell ratings. The average price target of $631.42 is near the current price, reflecting confidence in fundamentals and limited downside risk.
- Robust Profitability Metrics: Operating margin is 18.2% and net margin is 15.1%, both healthy for the industry. Q1 2026 gross margin improved to 40.7% from 37.3% in Q2 2025, indicating operational efficiency and pricing power.
- Diversified Revenue Streams: Revenue is spread across consumables ($4.722B), instruments ($1.555B), and services ($4.728B), with the services segment (including CRO) as a key growth driver. This diversification reduces reliance on any single product line or market.
Bearish
- Elevated Valuation Metrics: Trailing P/E is 32.61x and forward P/E is 22.87x, with a PEG ratio of 4.54x, indicating the stock is priced at a premium to its expected growth. This leaves little room for error and could lead to multiple compression if growth disappoints.
- Modest Upside to Analyst Target: The average analyst target of $631.42 implies only 0.34% upside from the current price of $629.27, suggesting the stock is fairly valued or fully priced. The low target of $520 implies a potential 17.4% downside.
- High Debt Levels: Debt-to-equity ratio is 0.74, indicating significant leverage. Interest expense was $354 million in Q1 2026, which could pressure earnings if rates rise or cash flow weakens.
- Inflation and Geopolitical Risks: Recent news highlights 'modest inflation' risk amid Middle East tensions, which could increase input costs and disrupt supply chains. This could pressure margins and growth if not managed effectively.
TMO Technical Analysis
Thermo Fisher's stock has demonstrated a robust recovery over the past year, with a 1-year price change of +30.08%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $629.27 sits at 97.7% of its 52-week range (between $435.27 and $643.99), indicating the stock is trading near its highs, reflecting strong bullish momentum and investor confidence. This positioning suggests the market is rewarding the company's operational performance and growth prospects, though it also implies limited upside from a purely technical perspective without a breakout above the 52-week high of $643.99.
Beta
0.85
0.85x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$644
Price range past year
Annual Return
+30.1%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +19.5% | +3.6% |
| 3m | +40.4% | +2.7% |
| 6m | +23.2% | +11.4% |
| 1y | +30.1% | +18.7% |
| ytd | +6.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Thermo Fisher's revenue trajectory remains solid, with the most recent quarter (Q1 2026) reporting revenue of $11.005 billion, up 6.18% year-over-year, accelerating from the 4.7% growth seen in Q1 2025. The multi-quarter trend shows consistent growth: Q2 2025 revenue was $10.855 billion, Q3 2025 was $11.122 billion, and Q4 2025 was $12.215 billion, indicating a steady upward trajectory. The growth is broad-based, with consumables ($4.722 billion), instruments ($1.555 billion), and services ($4.728 billion) all contributing, though the services segment (including CRO) is a key driver. This growth, while not explosive, demonstrates resilience and the company's ability to generate consistent demand across its diversified portfolio.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given Thermo Fisher's positive net income, the trailing P/E ratio of 32.61x is the primary valuation metric, with a forward P/E of 22.87x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests an anticipated EPS growth of approximately 42.6%, reflecting optimism about margin expansion and operational leverage. The PEG ratio of 4.54x indicates that the stock is priced at a premium to its expected growth rate, which could be a concern for value-oriented investors.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.74 and interest expense of $354 million in Q1 2026, which could strain cash flow if rates rise. The company's net margin of 15.1% is solid, but any margin erosion from inflation or competitive pricing could impact earnings. Additionally, the high PEG ratio of 4.54x implies that the stock is priced for significant growth, and any shortfall could lead to a sharp de-rating. Free cash flow is healthy at $6.748 billion TTM, but the payout ratio of 9.4% suggests limited dividend growth potential, which may not attract income investors.
FAQ
The key risks include: 1) Valuation risk - the stock is trading at a premium, so any disappointment in earnings could lead to multiple compression. 2) Financial risk - the company has a debt-to-equity ratio of 0.74, and rising interest rates could increase interest expenses. 3) Competitive risk - competitors like Danaher and Agilent could erode market share. 4) Macro risk - inflation and geopolitical tensions could disrupt supply chains and increase costs. The most severe risk is a combination of slowing growth and margin compression, which could lead to a significant de-rating.
The 12-month forecast for TMO is based on three scenarios: Bull case (25% probability) targets $680-$750, driven by stronger growth and margin expansion. Base case (50% probability) targets $600-$650, with steady growth and stable margins, aligning with the average analyst target of $631.42. Bear case (25% probability) targets $500-$550, if growth slows and margins compress. The most likely scenario is the base case, with the stock trading near its fair value. Investors should monitor quarterly results to see which scenario unfolds.
TMO is trading at a trailing P/E of 32.61x and a forward P/E of 22.87x, which is a premium to the market average. The PEG ratio of 4.54x suggests the stock is overvalued relative to its expected growth rate. Compared to its own history, the stock is trading near the high end of its valuation range, as it is close to its 52-week high. The market is pricing in significant earnings growth, as implied by the gap between trailing and forward P/E. Therefore, TMO appears overvalued based on traditional metrics, but its quality and growth prospects may justify a premium.
TMO is a high-quality company with strong fundamentals, but at the current price of $629.27, the stock is fairly valued with only 0.34% upside to the average analyst target of $631.42. The consensus rating is Buy, but the risk-reward is balanced. For long-term investors, TMO could be a good buy on any pullback to the $550-$580 range, which would offer a more attractive entry point. However, for short-term traders, the limited upside may not justify the risk. Overall, it is a good stock to own, but not necessarily at current levels.
TMO is best suited for long-term investment due to its stable growth, diversified portfolio, and moderate volatility (beta 0.847). The company has a consistent track record of revenue and earnings growth, making it a reliable compounder. Short-term trading may be less rewarding given the limited upside to analyst targets and the potential for valuation compression. A minimum holding period of 3-5 years is recommended to fully realize the benefits of its growth and dividend (yield 0.29%). For investors with a long-term horizon, TMO can serve as a core holding in a healthcare-focused portfolio.